KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 2464 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Multicenter, randomized, double-blind, placebo-controlled phase 3 study of mogamulizumab with open-label extension study in a minimum number of patients with human T-cell leukemia virus type-1-associated myelopathy. PMID 38430272 · J Neurol · 2024-Jun The study is a Phase III randomized trial with a drug intervention and primary results, but it is not an oncology (malignant neoplasm) study and does not have a time-to-event efficacy endpoint. Therefore, it is excluded from the oncology Kaplan-Meier digitization cohort.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy. PMID 38418343 · Eur Urol · 2024-Jun 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 2 Figure · 4 Panel · risk visible
A Multi-Institutional, Randomized, Phase III Trial Comparing Anatomical Segmentectomy and Lobectomy for Clinical Stage IA3 Pure-Solid Non-Small-Cell Lung Cancer: West Japan Oncology Group Study WJOG16923L (STEP UP Trial). PMID 38360496 · Clin Lung Cancer · 2024-Jun Excluded because the intervention is a non-drug surgical procedure, and the record is a protocol abstract without primary efficacy results.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE). PMID 38280448 · J Thorac Oncol · 2024-Jun 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial. PMID 38159809 · J Thorac Oncol · 2024-Jun 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial. PMID 38102374 · Clin Transl Oncol · 2024-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial. PMID 39075620 · Arthritis Res Ther · 2024-Jul-29 The report is a phase 3 randomized trial of a drug (upadacitinib) in humans, but the disease is rheumatoid arthritis, not oncology. It does not report a time-to-event efficacy endpoint (OS, PFS, etc.) or Kaplan-Meier/HR for such an endpoint.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. PMID 38971175 · Lancet · 2024-Jul-27 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Alliance A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer. PMID 39060961 · BMC Cancer · 2024-Jul-26 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study. PMID 39054491 · BMC Cancer · 2024-Jul-25 Study meets criteria for oncology, human, randomized, Phase III, drug intervention, and original results. However, it is ineligible because the primary endpoint is ORR (a categorical response rate), not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). No time-to-event data (Kaplan-Meier, HR) are reported.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study. PMID 39054485 · BMC Cancer · 2024-Jul-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302). PMID 39054430 · BMC Cancer · 2024-Jul-25 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type no_km 0 Figure · 0 Panel · risk not_applicable
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults. PMID 39047240 · N Engl J Med · 2024-Jul-25 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced Non-Small Cell Lung Cancer. PMID 38828957 · J Clin Oncol · 2024-Jul-20 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 4 Figure · 12 Panel · risk visible
21-Gene Recurrence Score and Survival Outcomes in the Phase III Multicenter TAILORx Clinical Trial. PMID 39019060 · J Natl Compr Canc Netw · 2024-Jul-17 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
An Economic Analysis of SC24 in Canada: A Randomized Study of SBRT Compared With Conventional Palliative RT for Spinal Metastases. PMID 38218455 · Int J Radiat Oncol Biol Phys · 2024-Jul-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer. PMID 38759121 · J Clin Oncol · 2024-Jul-10 The record is a Phase III randomized trial in oncology with a primary time-to-event endpoint (DFS), but it is ineligible because it lacks a drug-containing intervention, comparing only radiotherapy techniques.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Capecitabine or Capecitabine Plus Oxaliplatin Versus Fluorouracil Plus Cisplatin in Definitive Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (CRTCOESC): A Multicenter, Randomized, Open-Label, Phase 3 Trial. PMID 38710003 · J Clin Oncol · 2024-Jul-10 命中用户提供的消化道肿瘤阳性参考集。
H L S B
旧组与严格 v3 交集 eligiblepositive_reference confirmed 2 Figure · 8 Panel · risk visible
CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy. PMID 38552197 · J Clin Oncol · 2024-Jul-10 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 1 Figure · 1 Panel · risk visible
Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial. PMID 38876133 · Lancet · 2024-Jul-06 命中用户提供的消化道肿瘤阳性参考集。
H L S B
旧组与严格 v3 交集 eligiblepositive_reference needs_review 0 Figure · 0 Panel · risk not_assessed
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS. PMID 38394384 · Oncologist · 2024-Jul-05 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type no_km 0 Figure · 0 Panel · risk not_applicable
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer. PMID 38959480 · N Engl J Med · 2024-Jul-04 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Docetaxel-oxaliplatin-capecitabine/5-fluorouracil (DOX/F) followed by docetaxel versus oxaliplatin-capecitabine/5-fluorouracil (CAPOX/FOLFOX) in HER2-negative advanced gastric cancers. PMID 39067037 · JNCI Cancer Spectr · 2024-Jul-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 1 Figure · 2 Panel · risk visible
Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG-1216 Trial. PMID 38980676 · JAMA Netw Open · 2024-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study. PMID 38950925 · Int J Gynecol Cancer · 2024-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A Prospective Randomized Multicenter Study on the Impact of [18F]F-Choline PET/CT Versus Conventional Imaging for Staging Intermediate- to High-Risk Prostate Cancer. PMID 38844361 · J Nucl Med · 2024-Jul-01 The study is a Phase III randomized trial in oncology with time-to-event endpoints. However, it is excluded because the intervention is a diagnostic imaging agent (a radiopharmaceutical) and not a therapeutic drug intervention. The trial design focuses on comparing diagnostic modalities for staging, not the efficacy of a systemic anti-cancer treatment.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial). PMID 38664019 · J Nucl Med · 2024-Jul-01 The trial is a Phase III randomized oncology study with a primary time-to-event endpoint, but the intervention is a diagnostic imaging procedure, not a drug, which does not meet the requirement for a drug-containing intervention.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer. PMID 38648575 · J Clin Oncol · 2024-Jul-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 1 Figure · 2 Panel · risk visible
Secondary analysis of late major gastrointestinal and genitourinary toxicities in unfavorable-risk prostate cancer patients receiving docetaxel: Insights from a randomized trial. PMID 38427287 · Cancer · 2024-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis. PMID 38299578 · Haematologica · 2024-Jul-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Randomized Phase 3 Trial of the Hypoxia Modifier Nimorazole Added to Radiation Therapy With Benefit Assessed in Hypoxic Head and Neck Cancers Determined Using a Gene Signature (NIMRAD). PMID 38072326 · Int J Radiat Oncol Biol Phys · 2024-Jul-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Morbidity and Mortality After Laparoscopy-Assisted Distal Gastrectomy and Totally Laparoscopic Distal Gastrectomy to Treat Gastric Cancer: An Interim Report: A Phase III Multicenter, Prospective, Randomized Trial (The KLASS-07 Trial). PMID 38960885 · J Gastric Cancer · 2024-Jul 干预为非药物单独策略,未满足药物干预要求。
H L S B
旧组与严格 v3 交集 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of BP02 (Trastuzumab Biosimilar) in HER2-Positive Metastatic Breast Cancer: A Multicenter Phase III Study. PMID 38937403 · Clin Drug Investig · 2024-Jul The study is an eligible Phase III randomized oncology trial with a drug intervention, but the primary efficacy endpoint is objective response rate, not a time-to-event endpoint. The abstract does not report any time-to-event endpoint (e.g., OS, PFS, DFS) or related metrics (e.g., Kaplan-Meier curves, hazard ratios). Therefore, it does not meet the inclusion criteria for a time-to-event efficacy endpoint.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group. PMID 38936378 · Lancet Oncol · 2024-Jul 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Dendritic cells loaded with allogeneic tumour cell lysate plus best supportive care versus best supportive care alone in patients with pleural mesothelioma as maintenance therapy after chemotherapy (DENIM): a multicentre, open-label, randomised, phase 2/3 study. PMID 38848742 · Lancet Oncol · 2024-Jul 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial. PMID 38820979 · Lung Cancer · 2024-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer. PMID 38755096 · Ann Oncol · 2024-Jul 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 study. PMID 38749110 · Eur J Cancer · 2024-Jul 命中用户提供的消化道肿瘤阳性参考集。
H L S B
旧组与严格 v3 交集 eligiblepositive_reference needs_review 0 Figure · 0 Panel · risk not_assessed
Using the genomic adjusted radiation dose (GARD) to personalize the radiation dose in nasopharyngeal cancer. PMID 38636709 · Radiother Oncol · 2024-Jul The study is an original result report from a phase III randomized trial with a drug intervention, but the reported primary endpoint (locoregional failure free rate) is not a standard time-to-event efficacy endpoint (like OS, PFS, DFS), and the abstract does not mention Kaplan-Meier analysis or hazard ratios for this endpoint. The analysis is biomarker-focused (GARD) rather than a comparative drug efficacy analysis.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A multicentric randomized controlled phase III trial of adaptive and 18F-FDG-PET-guided dose-redistribution in locally advanced head and neck squamous cell carcinoma (ARTFORCE). PMID 38636708 · Radiother Oncol · 2024-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
First-line pembrolizumab plus chemotherapy for advanced/metastatic esophageal cancer: 1-year extended follow-up in the Japanese subgroup of the phase 3 KEYNOTE-590 study. PMID 38607538 · Esophagus · 2024-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study. PMID 38582713 · Eur Urol · 2024-Jul 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 1 Figure · 1 Panel · risk visible
The association of histopathologic features after neoadjuvant chemo-immunotherapy with clinical outcome: Sub-analyses from the randomized double-blinded, placebo-controlled, Phase III IMagyn050/GOG3015/ENGOT-ov39 study. PMID 38554625 · Gynecol Oncol · 2024-Jul 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
The Impact of Initial Tumor Response on Survival Outcomes of Patients With HER2-Positive Advanced Breast Cancer Treated With Docetaxel, Trastuzumab, and Pertuzumab: An Exploratory Analysis of the CLEOPATRA Trial. PMID 38514306 · Clin Breast Cancer · 2024-Jul 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Long term results of a prospective multicenter observational study on the use of anti-human T-lymphocyte immunoglobulin (ATLG) in unrelated donor transplantation (ATOS study). PMID 38493275 · Bone Marrow Transplant · 2024-Jul The record describes an observational study (ATOS) that references a prior Phase III randomised trial (RCT) for comparison. While it reports time-to-event efficacy endpoints for patients with haematological malignancies, the study itself is not the original report of a randomised trial with a drug intervention. The drug ATLG is used for GvHD prophylaxis in the context of unrelated donor transplantation, not as a primary cancer therapeutic drug intervention in a definitive randomised trial. The original RCT is not provided here. Therefore, the criteria for an original formal-result report of a Phase III randomised trial with a drug-containing intervention are not met.
H L S B
旧组与严格 v3 交集 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial. PMID 38460751 · J Thorac Oncol · 2024-Jul 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774). PMID 38290964 · Eur Urol · 2024-Jul This is a Phase III randomized trial in oncology with human patients and an original result. However, the intervention is diagnostic imaging (PSMA-PET/CT) and not a drug-containing intervention, and the primary/key secondary endpoint analyzed in this report is management change frequency (a categorical outcome), not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.). The report is explicitly a secondary endpoint analysis, and the primary time-to-event endpoint is planned for 2025.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Gemcitabine/nab-paclitaxel vs gemcitabine/carboplatin for advanced urothelial carcinoma. PMID 38009394 · BJU Int · 2024-Jul 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Predictors of three-month mortality and severe chemotherapy-related adverse events in patients aged 70 years and older with metastatic non-small-cell lung cancer: A secondary analysis of ESOGIA-GFPC-GECP 08-02 study. PMID 37211514 · J Geriatr Oncol · 2024-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration. PMID 38291372 · BMC Cancer · 2024-Jan-30 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type no_km 0 Figure · 0 Panel · risk not_applicable